EC antitrust probe homes in on Servier
This article was originally published in Scrip
The European Commission has sent objections to Servier and a number of generics firms in the latest step in its investigation into anticompetitive practices by pharmaceutical companies. Servier is accused of trying to limit generic competition to its cardiovascular medicine perindopril, both by buying up scarce technologies for the product's manufacture, and by inducing generics companies to sign settlements over patent challenges.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.